ArtiPlus
Presbyopia
Clinical TrialsActive
Key Facts
About Ophtec
Ophtec is a privately held, commercial-stage ophthalmic device company with over 40 years of heritage in developing intraocular lenses and surgical solutions. Its core business focuses on two segments: cataract surgery (offering monofocal, toric, and presbyopia-correcting IOLs) and refractive surgery (with its proprietary Artisan/Artiflex phakic IOLs). The company maintains a vertically integrated model with in-house R&D and manufacturing in Groningen, and has achieved significant regulatory milestones, including the first FDA approval for a phakic IOL in 2004. Its outlook is driven by an aging population, expansion of its premium IOL portfolio, and ongoing clinical development for next-generation lenses.
View full company profileTherapeutic Areas
Other Presbyopia Drugs
| Drug | Company | Phase |
|---|---|---|
| Presbyopia Treatment | Viatris (2) | Filed/Under Review |
| Flexivue Microlens | Presbia | Approved |
| LB-01 | Lento Bio | Discovery/IND-Enabling |
| LB-02 | Lento Bio | Discovery |
| Presbyopia-Correcting Contact Lenses | Clerio Vision | Development |
| Intra-corneal Implant | MAG Optics | Pre-clinical |
| Novel Presbyopia & Refractive Therapies | Bausch + Lomb | Clinical Development |
| NVK029 | Vyluma | Phase 2 |
| BRIMOCHOL™ PF | Tenpoint Therapeutics | NDA Submitted |
| DE-128A | Santen Pharmaceutical | Phase 2 |
| YP-10 | Viatris | NDA Filed |
| VIZZ™ (aceclidine ophthalmic solution) 1.44% | LENZ Therapeutics | Approved |